Literature DB >> 12574267

Use of a phage-based assay for phenotypic detection of mycobacteria directly from sputum.

D J Park1, F A Drobniewski, A Meyer, S M Wilson.   

Abstract

The phage amplified biologically assay is a new method for rapid and low-cost phenotypic determination of the drug sensitivities of Mycobacterium tuberculosis isolates and the detection of viable organisms in patient specimens. Infection of slowly growing mycobacteria with phage (phage D29) was followed by chemical virucide destruction of extracellular phage. Infected mycobacteria were mixed in culture with rapidly growing sensor cells, which the phage can also infect; i.e., lytic amplification of phage occurs. The aims of the present study were to optimize the speed and sensitivity of the assay and reduce its cost for developing countries by using an M. tuberculosis-spiked sputum model with (i). identification of inhibitory components of sputum and optimization of decontamination methods; (ii). simplification of the washing and development steps; (iii). reduction of the use of high-cost components, e.g., oleate-albumin-dextrose-catalase (OADC) supplement; and (iv). optimization of virucide treatment. The following results were obtained. (i). An inhibitory factor in sputum which could be removed by treatment of the sample with sodium dodecyl sulfate or NaOH decontamination was identified. (ii). A microcentrifuge-based approach with thixotropic silica as a bedding and resuspension agent was developed as an alternative to conventional centrifugation medium exchange. The yield was increased 228-fold, with increased speed and reduced cost. (iii). At present, after extracellular inactivation of phage, the ferrous ammonium sulfate (FAS) virucide is sequestered by dilution with an expensive supplement, OADC. Sodium citrate with calcium chloride was found to be a cost-effective after treatment with the FAS protectant and offered greater protection than OADC. Kinetic-lysis experiments indicated that an infection time of 1 to 3 h prior to FAS addition was optimal. (iv). Amplification of the signal (which corresponded to the burst size) was shown by allowing lysis prior to plating in a spiked medium model (up to 20-fold) and a spiked sputum model (up to 10-fold). A liquid culture detection method capable of detecting approximately 60 viable M. tuberculosis organisms in 1 ml of sputum was developed. Taken together, these improvements support the routine application of the assay to sputum specimens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574267      PMCID: PMC149652          DOI: 10.1128/JCM.41.2.680-688.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

Authors:  C Dye; G P Garnett; K Sleeman; B G Williams
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

2.  The use of luciferase-reporter phage for antibiotic-susceptibility testing of mycobacteria.

Authors:  P F Riska; W R Jacobs
Journal:  Methods Mol Biol       Date:  1998

3.  New biomolecular assays must be tested by direct study in the developing world.

Authors:  F A Drobniewski; S M Wilson
Journal:  BMJ       Date:  1998-03-21

4.  Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  S M Wilson; Z al-Suwaidi; R McNerney; J Porter; F Drobniewski
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

5.  Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis.

Authors:  I J Eltringham; F A Drobniewski; J A Mangan; P D Butcher; S M Wilson
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

6.  Rapid film-based determination of antibiotic susceptibilities of Mycobacterium tuberculosis strains by using a luciferase reporter phage and the Bronx Box.

Authors:  P F Riska; Y Su; S Bardarov; L Freundlich; G Sarkis; G Hatfull; C Carrière; V Kumar; J Chan; W R Jacobs
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Conditionally replicating luciferase reporter phages: improved sensitivity for rapid detection and assessment of drug susceptibility of Mycobacterium tuberculosis.

Authors:  C Carrière; P F Riska; O Zimhony; J Kriakov; S Bardarov; J Burns; J Chan; W R Jacobs
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

8.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  A Pablos-Méndez; M C Raviglione; A Laszlo; N Binkin; H L Rieder; F Bustreo; D L Cohn; C S Lambregts-van Weezenbeek; S J Kim; P Chaulet; P Nunn
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

9.  Inactivation of mycobacteriophage D29 using ferrous ammonium sulphate as a tool for the detection of viable Mycobacterium smegmatis and M. tuberculosis.

Authors:  R McNerney; S M Wilson; A M Sidhu; V S Harley; Z al Suwaidi; P M Nye; T Parish; N G Stoker
Journal:  Res Microbiol       Date:  1998 Jul-Aug       Impact factor: 3.992

10.  L5 luciferase reporter mycobacteriophages: a sensitive tool for the detection and assay of live mycobacteria.

Authors:  G J Sarkis; W R Jacobs; G F Hatfull
Journal:  Mol Microbiol       Date:  1995-03       Impact factor: 3.501

View more
  13 in total

1.  Development of a bacteriophage phage replication assay for diagnosis of pulmonary tuberculosis.

Authors:  Ruth McNerney; Bupe S Kambashi; Juliana Kinkese; Ruth Tembwe; Peter Godfrey-Faussett
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 2.  Application of bacteriophages for detection of foodborne pathogens.

Authors:  Mathias Schmelcher; Martin J Loessner
Journal:  Bacteriophage       Date:  2014-02-07

3.  Comparison of the performances of two in-house rapid methods for antitubercular drug susceptibility testing.

Authors:  Agustina I de la Iglesia; Emma J Stella; Héctor R Morbidoni
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

4.  Development of phage-based assay to differentiate ciprofloxacin resistant and sensitive Salmonella Typhimurium.

Authors:  Nana Nguefang Laure; Juhee Ahn
Journal:  Food Sci Biotechnol       Date:  2021-01-06       Impact factor: 2.391

Review 5.  Phage Amplification Assay for Detection of Mycobacterial Infection: A Review.

Authors:  Monika Beinhauerova; Iva Slana
Journal:  Microorganisms       Date:  2021-01-23

6.  Phage-based platforms for the clinical detection of human bacterial pathogens.

Authors:  David A Schofield; Natasha J Sharp; Caroline Westwater
Journal:  Bacteriophage       Date:  2012-04-01

7.  In-house, simple & economical phage technique for rapid detection of rifampicin, isoniazid, ethambutol, streptomycin & ciprofloxacin drug resistance using Mycobacterium tuberculosis isolates.

Authors:  Nanda Hemvani; Vikas Patidar; D S Chitnis
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

8.  A multi-center study to evaluate the performance of phage amplified biologically assay for detecting TB in sputum in the pulmonary TB patients.

Authors:  Changtai Zhu; Zhenling Cui; Ruijuan Zheng; Hua Yang; Ruiliang Jin; Lianhua Qin; Zhonghua Liu; Jie Wang; Zhongyi Hu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

9.  Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis.

Authors:  Matthew C Mulvey; Katherine A Sacksteder; Leo Einck; Carol A Nacy
Journal:  mBio       Date:  2012-03-13       Impact factor: 7.867

10.  Bacteriophage amplification assay for detection of Listeria spp. using virucidal laser treatment.

Authors:  I C Oliveira; R C C Almeida; E Hofer; P F Almeida
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.